Racura OncologyASX:RAC -5.96%31 Market Cap is A$460.76 Mil as of Jun. 26, 2026. GuruFocus rates ASX:RAC with a GF Score™ of 31/100. Among 1,431 Biotechnology companies, Racura Oncology ranks better than 65.55% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Racura Oncology's share price for the quarter that ended in Dec. 2025 was A$2.73. Racura Oncology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 180.82 Mil. Therefore, Racura Oncology's market cap for the quarter that ended in Dec. 2025 was A$493.64 Mil.
Racura Oncology's quarterly market cap
declined
from Dec. 2024 (A$234.51 Mil) to Jun. 2025 (A$204.15 Mil) but then
increased
from Jun. 2025 (A$204.15 Mil) to Dec. 2025 (A$493.64 Mil).
Racura Oncology's annual market cap
increased
from Jun. 2023 (A$199.76 Mil) to Jun. 2024 (A$310.80 Mil) but then
declined
from Jun. 2024 (A$310.80 Mil) to Jun. 2025 (A$204.15 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Racura Oncology's Enterprise Value for Today is A$439.82 Mil.
Racura Oncology (ASX:RAC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Racura Oncology Market Cap Related Terms
Racura Oncology Market Cap Historical Data
* Premium members only.
The historical data trend for Racura Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RAC vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Racura Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Racura Oncology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Racura Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Racura Oncology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Racura Oncology's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Racura Oncology (ASX:RAC) has a Market Cap of A$460.76 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Racura Oncology and its competitors. According to the industry distribution chart, Racura Oncology ranks #493 out of 1431 companies in the Biotechnology industry, placing it in the top 34.5%.
Is Racura Oncology's Market Cap too high?
Racura Oncology's current Market Cap is A$460.76 Mil. Based on the distribution chart, Racura Oncology ranks #493 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #493 out of 1431 companies for Market Cap. This puts Racura Oncology in the upper half of its industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Racura Oncology and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Racura Oncology's current Market Cap is A$460.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Market Cap of A$460.76 Mil. The current Market Cap is A$460.76 Mil. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Market Cap is A$460.76 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score
Get the complete analysis for ASX:RAC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAC has been successfully added to your 
